Mark R Hellberg

This inventor holds 89 USPTO granted patents and 19 published patent applications, plus 1 CIPO patent and 4 EPO patents, primarily in Ophthalmic Therapeutics (CPC class C07C-). Top assignees: Alcon Laboratories, Inc., Alcon, Inc., Alcon Universal Ltd.. Active years: 1991-2018.

USPTO Granted Patents = 89 (Patent Applications = 19)

% Patents Active = 60.7

CIPO Patents = 1 (Patent Applications = 3)

EPO Patents = 4 (Patent Applications = 6)

Average Co-Inventor Count = 2.9

ph-index = 16

Forward Citations = 726(Granted Patents)

Forward Citations (Not Self Cited) = 690(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Fort Worth, TX (US) (1999)
Highland Village, TX (US) (2003 - 2010)
Needham, MA (US) (2015)
Arlington, TX (US) (1991 - 2018)

Company Filing History:

32 out of 449

Alcon Laboratories, Inc.

Alcon Manufacturing, Ltd.

patents

6. 5 out of 10

Shire Orphan Therapies Gmbh

patents

7. 3 out of 218

A. H. Robins Company, Incorporated

American Home Products Corporation

Shire Orphan Thereapies Gmbh

patent

13. 2 out of 834,411

Other

patents

where one patent can have more than one assignee

Years Active: 1991-2018

Loading Chart...

Areas of Expertise:

NPR-B Agonists

Ocular Analgesics

Glaucoma Treatments

Superoxide Dismutase

Dry Eye Disorders

Inflammatory Diseases

Prostaglandins

Rho Kinase Inhibitors

PDE4 Inhibitors

Angiogenesis

Ocular Hypertension

Corneal Penetration

89 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9982016 - NPR-B agonists (2018-05-29),

2. 9822147 - Methods of treating ophthalmic diseases using NPR-B agonists (2017-11-21),

3. 9745344 - NPR-B agonists (2017-08-29),

4. 9458198 - Cyclic peptide-based NPR-B agonists (2016-10-04),

5. 9187525 - Methods of treating ophthalmic diseases using NPR-B agonists (2015-11-17),

6. 9187468 - Topical ocular analgesic agents (2015-11-17),

7. 9169293 - NPR-B agonists (2015-10-27),

8. 8551938 - NPR-B agonists (2013-10-08),

9. 8546523 - NPR-B agonists (2013-10-01),

10. 8252793 - Bradykinin receptor agonists and uses thereof to treat ocular hypertension and glaucoma (2012-08-28),

11. 8138205 - Heteroarylalkoxy-substituted quinolone inhibitors of PDE4 (2012-03-20),

12. 8067405 - Superoxide dismutase mimics for the treatment of ocular disorders and diseases (2011-11-29),

13. 8003635 - Superoxide dismutase mimics for the treatment of ocular disorders and diseases (2011-08-23),

14. 7923471 - Method of treating dry eye disorders and uveitis (2011-04-12),

15. 7906512 - 3,6-substituted imidazol[1,2-b]pyridazine analogs for treating allergic and inflammatory diseases (2011-03-15),

Title: Mark R Hellberg: Pioneering Tech Inventor

Introduction:

Mark R Hellberg, a visionary inventor based in Arlington, TX (US), has made significant contributions to the tech industry with his passion for innovation and relentless pursuit of excellence. His impressive portfolio of 89 patents is a testament to his ingenuity and dedication to advancing technology.

Latest Patents:

Hellberg's latest patents include groundbreaking inventions in the field of ophthalmic treatments using NPR-B agonists. These novel compounds, particularly linear peptides containing 8-13 amino acid residues, demonstrate NPR-B agonistic activity and offer promising methods for treating various eye diseases.

Career Highlights:

Having worked with esteemed companies such as Alcon Laboratories, Inc. and Alcon, Inc., Hellberg has honed his skills and expertise in the tech industry. His innovative solutions have not only revolutionized ophthalmic treatments but have also paved the way for future advancements in the field.

Collaborations:

Hellberg's collaborative efforts with coworkers like Peter G Klimko and Gustav Graff have been instrumental in bringing his inventions to life. Through teamwork and shared dedication to innovation, they have successfully translated groundbreaking ideas into tangible products that benefit society.

Conclusion:

Mark R Hellberg's remarkable journey as a pioneering inventor underscores his unwavering commitment to pushing the boundaries of technology and improving lives through his groundbreaking inventions. His legacy serves as an inspiration to aspiring inventors and a testament to the power of innovation in shaping the future of the tech industry.